Navigation Links
Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Antigenics Pharmaceuticals is to start its Phase III cancer vaccine trial against Melanoma which is a type of skin cancer. Oncophage is the new skin cancer vaccine developed by Antigenics.// The vaccine trial of Oncophage which was conducted in 322 patients failed to meet the required statistically significance results compared to prolongation in survival and the vaccine was not shown to have any better results compared to other cancer treatments.

But, earlier studies with Oncophage showed a group of patients with the least-advanced severity of melanoma in the trial lived 20.9 months on Oncophage compared to 12.8 months for those patients taking standard drugs, the company said. The difference had not yet reached statistical significance and the trial is continuing.

Antigenics is to start a Phase III study next year to test its vaccine on a more responsive group, patients with Stage IV M1a patients. Though, the trial is to cost the company more than $12 million the scientists of the company are confident over the results.

Needham & Co. analyst Mark Monane in a research note called the data "encouraging" but only "hypothesis-generating rather than hypothesis-confirming, that we believe that any intensive reading into the data at this stage may be premature."
'"/>




Page: 1

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
4. Top Pharmaceuticals Influence Doctors Prescriptions
5. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
6. Personalized Medicine and Innovative Pharmaceuticals
7. Pravastatin Launched by Watson Pharmaceuticals
8. Tata Industries picks up stake in Indigene Pharmaceuticals
9. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
10. OPPI Opposes Draft National Pharmaceuticals Policy
11. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology: